Efficacy of nonsurgical tigecycline pleurodesis for the management of hepatic hydrothorax in patients with liver cirrhosis

Surgical Case Reports

Table 1 Laboratory results of the patients

	Case 1			Case 2
	Before pleurodesis	After pleurodesis, first 2 weeks (median)	Late follow-up	Before pleurodesis	After pleurodesis, first 2 weeks (median)	Late follow-up
CBC
WBC, 10³/mm³	3	1.6^a	4.4	5.9	7.1	4.4
Hb, g/dl	10.3	8.6^a	11.3	10	10.6	9.4
Plt, 10³/mm³	49	32	34	150	158	114
INR, range (0.8–1.2)	1.49	2.2^a	1.6	1.14	1.19	1.17
AST/ALT, IU/l	59/47	50/30	68/77	36/127	23/17	26/13
GGT/AP, IU/l	17/97	12/71	47/81	26/81	37/127	36/85
T.bil/D.bil, mg/dl	2.1/0.63	2.2/ 0.4	3.74/1.07	1.08/0.3	1.1/0.2	1.4/0.39
Albumin, g/dl	2	2.3	2.4	2.6	2.7	3
Creatinine, mg/dl	0.6	0.57	0.6	0.7	0.7	0.7
Na, mEq/l	134	133	132	141	133	140
MELD score	14	18^a	17	9	9	9
CTP class	B	B	B	A	A	A

Abbreviations: CBC complete blood count, INR international normalized ratio, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma-glutamyl transpeptidase, AP alkaline phosphatase, Na sodium, K potassium, CTP Child–Turcotte–Pugh, MELD model for end-stage liver disease, Plt platelet, T.bil total bilirubin, D.bil direct bilirubin
^aPathologic changes